ReviewImmunological reviews2026
Oxidative Post-Translational Modifications of Insulin in Type 1 Diabetes Autoimmunity.
Review in Immunological reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 1 diabetes (T1D) is characterized by T cell-mediated destruction of insulin producing pancreatic β cells. However, stressed β cells are increasingly recognized as active contributors to disease pathogenesis rather than passive targets of immune attack. In this context, oxidative stress in β cells may promote oxidative post-translational modifications (oxPTMs) of insulin, generating modified insulin forms that have emerged as potential drivers of neoantigen formation and autoimmune responses. Due to their exceptionally high insulin biosynthetic load, limited antioxidant defenses, and susceptibility to endoplasmic reticulum and mitochondrial stress, β cells operate in an environment permissive to oxidative protein modification. Multiple studies have demonstrated that insulin is susceptible to several oxidative and nonenzymatic modifications, including oxidation, chlorination, nitration, and glycation, generating structurally distinct proteoforms with altered biological and immunological properties. Importantly, oxidatively modified insulin species (oxPTM-insulin) are recognized by both autoantibodies and autoreactive T cells in individuals with T1D, supporting their role as neoantigens. In this review, we discuss the mechanisms leading to oxPTM-insulin generation, summarize the biochemical and immunological evidence supporting their relevance in T1D, and examine the methodological challenges and controversies surrounding their identification. Finally, we explore the potential of oxPTM-insulin as a biomarker and therapeutic target in T1D.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.